Prophylactic Magnesium Sulfate and Sepsis in Preterm neonates with Respiratory Distress Syndrome

Investigating the effectiveness of magnesium sulfate prophylaxis to prevent hospital sepsis among premature infants with respiratory distress syndrome.

A clinical trial study that is both superior and parallel, using two intervention and control groups. Random allocation software was used to create a list of random blocks with variable sizes of 4 and 6, each block having an equal number of groups. The package will be used to conceal allocations using envelopes. The envelopes will have their numbers and be arranged in order. Then, for each patient entered into the study, an envelope will be opened and based on the contents of the envelope, they will be entered into one of the two control or intervention groups.

In the neonatal intensive care unit, serum magnesium levels are tested for premature babies aged 28 to 34 weeks, who weigh 1200 to 2000 grams and have respiratory distress syndrome 24 hours after birth. The control group received the usual treatment, while in the intervention group, intravenous magnesium sulfate was prescribed for 5 days.

Inclusion criteria: 28 to 34 weeks premature newborns with a weight of 1200 to 2000 grams with respiratory distress syndrome. Inclusion in the study is contingent on taking magnesium sulfate during pregnancy, neonatal anomaly, chorioamnionitis, and underlying maternal disease.

The intervention group took intravenous magnesium sulfate for 5 days, and the magnesium level was rechecked the day after the treatment. The control group received nutrition and, if necessary, routine TPN that did not contain magnesium.

The duration of assisted ventilation (whether it involves invasive or non-invasive ventilation) and the amount of time needed to receive complete oral nutrition (equivalent to 180 cc per kilogram of body weight).

A list of random blocks with variable sizes of 4 and 6 is created by using random allocation software. Each block has an equal number of groups and a number is assigned to it. The order of contents in each block is determined by the balanced distribution of people in the studied groups. Upon each patient's visit, one of the blocks is randomly selected and, according to the contents, the patient is assigned to one of the groups.

The analyst and the patient will be unaware of the intervention and control groups. Using random allocation software, a list of random blocks with variable sizes of 4 and 6 is designed, each block contains an equal number of groups, and a number is assigned to each block. The order of the contents of each block includes the balanced allocation of people in are the studied groups. With the visit of each patient, one of the blocks is randomly selected and according to the order of the contents, the patient is assigned to one of the groups.

All data can be shared after patients are made unidentifiable.

Data can be accessible 6 months after results are published.

Data can be accessible through an email to the corresponding author

Data will be available for researchers in universities and other scientific institute

After sending a request email to the corresponding author data will be sent in 1 month. email

Carrying out analysis on data is permitted. This process involves gathering information using a suitable software or tool that allows statisticians and data scientists to explore the data and find patterns in it. Then, based on that information and data, you can make a decision or draw a final conclusion.